genes. The top two thirds of our predictions exhibited threefold higher efficacy than that of the remaining fraction, confirming the accuracy of the algorithm.
Using this algorithm, we designed a wholegenome sgRNA library consisting of sequences predicted to have higher efficacy (table S8) . As with the sgRNA pool used in our screens, this new collection was also filtered for potential offtarget matches. This reference set of sgRNAs may be useful both for targeting single genes as well as large-scale sgRNA screening.
Taken together, these results demonstrate the utility of CRISPR-Cas9 for conducting large-scale genetic screens in mammalian cells. On the basis of our initial experiments, this system appears to offer several powerful features that together provide substantial advantages over current functional screening methods.
First, CRISPR-Cas9 inactivates genes at the DNA level, making it possible to study phenotypes that require a complete loss of gene function to be elicited. In addition, the system should also enable functional interrogation of nontranscribed elements, which are inaccessible by means of RNAi.
Second, a large proportion of sgRNAs successfully generate mutations at their target sites. Although this parameter is difficult to directly assess in pooled screens, we can obtain an estimate by examining the "hit rate" at known genes. Applying a z score analysis of our positive selection screens, we found that over 75% (46 of 60) of sgRNAs score at a significance threshold that perfectly separates true and false positives on a gene level ( fig. S5 , A to D). Together, these results show that the effective coverage of our library is very high and that the rate of false negatives should be low, even in a large-scale screen.
Third, off-target effects do not appear to seriously hamper our screens, according to several lines of evidence. Direct sequencing of potential off-target loci detected minimal cleavage at secondary sites, which typically reside in noncoding regions and do not affect gene function. Moreover, in the 6-TG screens the 20 most abundant sgRNAs all targeted one of the four members of the MMR pathway. In total, they represented over 30% of the final pool, which is a fraction greater the next 400 sgRNAs combined. In the etoposide screen, the two top genes scored far above background levels (P values 100-fold smaller than that of the next best gene), enabling clear discrimination between true and false-positive hits. Last, new versions of the CRISPR-Cas9 system have recently been developed that substantially decrease off-target activity (30, 31) .
Although we limited our investigation to proliferation-based phenotypes, our approach can be applied to a much wider range of biological phenomena. With appropriate sgRNA libraries, the method should enable genetic analyses of mammalian cells to be conducted with a degree of rigor and completeness currently possible only in the study of microorganisms. from the U.S. National Science Foundation (T.W. A major goal since the completion of the Human Genome Project is the functional characterization of all annotated genetic elements in normal biological processes and disease (1). Genome-scale loss-of-function screens have provided a wealth of information in diverse model systems (2) (3) (4) (5) . In mammalian cells, RNA interference (RNAi) is the predominant method for genome-wide loss-of-function screening (2, 3), but its utility is limited by the inherent incompleteness of protein depletion by RNAi and confounding off-target effects (6, 7) .
The RNA-guided CRISPR (clustered regularly interspaced short palindrome repeats)-associated nuclease Cas9 provides an effective means of introducing targeted loss-of-function mutations at specific sites in the genome (8, 9). Cas9 can be programmed to induce DNA double-strand breaks (DSBs) at specific genomic loci (8, 9) through a synthetic single-guide RNA (sgRNA) (10) , which when targeted to coding regions of genes can create frame shift insertion/deletion (indel) mutations that result in a loss-of-function allele. Because the targeting specificity of Cas9 is conferred by short guide sequences, which can be easily generated at large scale by array-based oligonucleotide library synthesis (11), we sought to explore the potential of Cas9 for pooled genome-scale functional screening.
Lentiviral vectors are commonly used for delivery of pooled short-hairpin RNAs (shRNAs) in RNAi because they can be easily titrated to control transgene copy number and are stably maintained as genomic integrants during subsequent cell replication (2, 12, 13) . Therefore, we designed a single lentiviral vector to deliver Cas9, a sgRNA, and a puromycin selection marker into target cells (lentiCRISPR) (Fig. 1A) . The ability to simultaneously deliver Cas9 and sgRNA through a single vector enables application to any cell type of interest, without the need to first generate cell lines that express Cas9.
To determine the efficacy of gene knockout by lentiCRISPR transduction, we tested six sgRNAs targeting enhanced green fluorescent protein (EGFP) in a human embryonic kidney (HEK) 293T cell line containing a single copy of EGFP ( fig. S1 ). After transduction at a low multiplicity of infection (MOI = 0.3) followed by selection with puromycin, lentiCRISPRs abolished EGFP fluorescence in 93 T 8% (mean T SD) of cells after 11 days (Fig. 1B) . Deep sequencing of the EGFP locus revealed a 92 T 9% indel frequency (n ≥ 10 4 sequencing reads per condition) ( fig. S2 ). In contrast, transduction of cells with lentiviral vectors expressing EGFP-targeting shRNA led to incomplete knockdown of EGFP fluorescence (Fig. 1C) .
Given the high efficacy of gene knockout by lentiCRISPR, we tested the feasibility of conducting genome-scale CRISPR-Cas9 knockout (GeCKO) screening with a pooled lentiCRISPR library. We designed a library of sgRNAs targeting 5′ constitutive exons ( Fig. 2A) of 18,080 genes in the human genome with an average coverage of 3 to 4 sgRNAs per gene (table S1), and each target site was selected to minimize off-target modification (14) (see supplementary text).
To test the efficacy of the full GeCKO library at achieving knockout of endogenous gene targets, we conducted a negative selection screen by profiling the depletion of sgRNAs targeting essential survival genes ( Fig. 2A) . We transduced the human melanoma cell line A375 and the human 
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www.sciencemag.org SCIENCE VOL 343 3 JANUARY 2014 stem cell line HUES62 with the GeCKO library at a MOI of 0.3. As expected, deep sequencing (figs. S3 and S4) 14 days after transduction revealed a significant reduction in the diversity of sgRNAs in the surviving A375 and HUES62 cells (Fig. 2 , B and C) (Wilcoxon rank sum test, P < 10
for both cell types). Gene set enrichment analysis (GSEA) (15) indicated that most of the depleted sgRNAs targeted essential genes such as ribosomal structural constituents (Fig. 2, D and E, and tables S2 and S3). The overlap in highly depleted genes and functional gene categories between the two cell lines ( fig. S5) indicates that GeCKO can identify essential genes and that enrichment analysis of depleted sgRNAs can pinpoint key functional gene categories in negative selection screens.
To test the efficacy of GeCKO for positive selection, we sought to identify gene knockouts that result in resistance to the BRAF protein kinase inhibitor vemurafenib (PLX) in melanoma (16) (Fig. 3A) . Exposure to PLX resulted in growth arrest of transduced A375 cells, which harbor the V600E gain-of-function BRAF mutation (17) (Fig. 3B) , therefore enabling the enrichment of a small group of cells that were rendered drugresistant by Cas9:sgRNA-mediated modification. After 14 days of PLX treatment, the sgRNA distribution was significantly different when compared with vehicle-treated cells (Fig. 3C ) (Wilcoxon rank-sum test, P < 10
) and clustered separately from all other conditions (Fig. 3D and fig. S6 ).
For a subset of genes, we found enrichment of multiple sgRNAs that target each gene after 14 days of PLX treatment (Fig. 3E) , suggesting that loss of these particular genes contributes to PLX resistance. We used the RNAi Gene Enrichment Ranking (RIGER) algorithm to rank screening hits by the consistent enrichment among multiple sgRNAs targeting the same gene ( Fig.  3F and table S4 ) (12) . Our highest-ranking genes included previously reported candidates NF1 and MED12 (18, 19) and also several genes not previously implicated in PLX resistance, including neurofibromin 2 (NF2), Cullin 3 E3 ligase (CUL3), and members of the STAGA histone acetyltransferase complex (TADA1 and TADA2B). These candidates yield new testable hypotheses regarding PLX resistance mechanisms (see supplementary text). For example, NF1 and NF2, although unrelated in sequence, are each mutated in similar but distinct forms of neurofibromatosis (20) . In addition, epigenetic dysregulation resulting from mutations in the mechanistically related STAGA and Mediator complexes (21) may have a role in acquired drug resistance. All of these hits were also identified through a second independent library transduction (figs. S7 and S8 and tables S5 and S6).
A similar screen to identify PLX drug resistance in A375 cells was previously conducted using a pooled library of 90,000 shRNAs (19) . To compare the efficacy and reliability of genome-scale shRNA screening with GeCKO, we used several methods to evaluate the degree of consistency among the sgRNAs or shRNAs targeting the top candidate genes. First, we plotted the P values for the top 100 hits using either RIGER (Fig. 4A) 20 T 12% of shRNAs targeting each gene ranked among the top 5% of enriched shRNAs (Fig. 4B) . We validated top-ranking genes from the GeCKO screen individually using 3 to 5 sgRNAs (Fig. 4 , C to E, and figs. S10 and S11). For NF2, we found that 4 out of 5 sgRNAs resulted in >98% allele modification 7 days after transduction, and all 5 sgRNAs showed >99% allele modification 14 days after transduction (Fig. 4C) . We compared sgRNA and shRNA-mediated protein depletion and PLX resistance using Western blot (Fig. 4D ) and cell growth assays (Fig. 4E) . Interestingly, although all five sgRNAs conferred resistance to PLX, only the best shRNA achieved sufficient knockdown to increase PLX resistance (Fig. 4E) , suggesting that even low levels of NF2 are sufficient to retain sensitivity to PLX. Additionally, sgRNAs targeting NF1, MED12, CUL3, TADA1, and TADA2B led to a decrease in protein expression and increased resistance to PLX (figs. S10 and S11). Deep sequencing confirmed a high rate of mutagenesis at targeted loci (figs. S12 and S13), with a small subset of off-target sites exhibiting indels (figs. S14 to S16), which may be alleviated using an offset nicking approach (22, 23) that was recently shown to reduce off-target modifications (22) .
GeCKO screening provides a mechanistically distinct method from RNAi for systematic perturbation of gene function. Whereas RNAi reduces protein expression by targeting RNA, GeCKO introduces loss-of-function mutations into genomic DNA. Although some indel mutations are expected to maintain the reading frame, homozygous knockout yields high screening sensitivity, which is especially important in cases where incomplete knockdown retains gene function. In addition, RNAi is limited to transcripts, whereas Cas9:sgRNAs can target elements across the entire genome, including promoters, enhancers, introns, and intergenic regions. Furthermore, catalytically inactive mutants of Cas9 can be tethered to different functional domains (23) (24) (25) (26) (27) to broaden the repertoire of perturbation modalities, including genome-scale gain-of-function screening using Cas9 activators and epigenetic modifiers. In the GeCKO screens presented here, the efficiency of complete knockout, the consistency of distinct sgRNAs, and the high validation rate for top screen hits demonstrate the potential of Cas9: sgRNA-based technology to transform functional genomics. www.sciencemag.org SCIENCE VOL 343 3 JANUARY 2014
